IS5274A - Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni - Google Patents

Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni

Info

Publication number
IS5274A
IS5274A IS5274A IS5274A IS5274A IS 5274 A IS5274 A IS 5274A IS 5274 A IS5274 A IS 5274A IS 5274 A IS5274 A IS 5274A IS 5274 A IS5274 A IS 5274A
Authority
IS
Iceland
Prior art keywords
therapeutic
inhibition
contained
protein bar
bar syndrome
Prior art date
Application number
IS5274A
Other languages
English (en)
Other versions
IS2097B (is
Inventor
Adelman Burt
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS5274A publication Critical patent/IS5274A/is
Publication of IS2097B publication Critical patent/IS2097B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
IS5274A 1997-06-20 1999-11-26 Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni IS2097B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (2)

Publication Number Publication Date
IS5274A true IS5274A (is) 1999-11-26
IS2097B IS2097B (is) 2006-04-12

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5274A IS2097B (is) 1997-06-20 1999-11-26 Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni

Country Status (25)

Country Link
US (1) US20020119151A1 (is)
EP (1) EP1034001B1 (is)
JP (1) JP2002504910A (is)
KR (1) KR100567998B1 (is)
CN (2) CN1651071A (is)
AT (1) ATE272408T1 (is)
AU (1) AU733062B2 (is)
BG (1) BG64436B1 (is)
BR (1) BR9810755A (is)
CA (1) CA2294138A1 (is)
CZ (1) CZ295805B6 (is)
DE (1) DE69825473T2 (is)
EA (1) EA002512B1 (is)
EE (1) EE9900587A (is)
ES (1) ES2226152T3 (is)
HK (1) HK1031825A1 (is)
HU (1) HUP0002048A3 (is)
IL (1) IL133305A0 (is)
IS (1) IS2097B (is)
NO (1) NO996274L (is)
NZ (1) NZ502051A (is)
PT (1) PT1034001E (is)
SK (1) SK285962B6 (is)
TR (1) TR199903141T2 (is)
WO (1) WO1998058672A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002898A (es) * 1998-09-21 2002-06-04 Genetics Inst Metodos de modulacion descendente de la respuesta inmune a proteinas terapeuticas.
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030298A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
EP2239271A1 (en) * 2003-06-13 2010-10-13 Biogen Idec MA Inc. Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
SI1682180T1 (sl) 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
US8647625B2 (en) 2004-07-26 2014-02-11 Biogen Idec Ma Inc. Anti-CD154 antibodies
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012158789A2 (en) 2011-05-17 2012-11-22 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
BR9807471A (pt) * 1997-01-10 2000-03-21 Biogen Inc Uso do composto anti-cd40l

Also Published As

Publication number Publication date
PT1034001E (pt) 2004-12-31
WO1998058672A1 (en) 1998-12-30
CZ295805B6 (cs) 2005-11-16
BG64436B1 (en) 2005-02-28
ES2226152T3 (es) 2005-03-16
EP1034001A1 (en) 2000-09-13
DE69825473T2 (de) 2005-08-04
KR100567998B1 (ko) 2006-04-07
ATE272408T1 (de) 2004-08-15
SK180399A3 (en) 2000-06-12
AU8153698A (en) 1999-01-04
EA200000059A1 (ru) 2000-08-28
BG104092A (en) 2000-10-31
CZ458899A3 (cs) 2000-04-12
CA2294138A1 (en) 1998-12-30
AU733062B2 (en) 2001-05-03
BR9810755A (pt) 2000-08-15
EE9900587A (et) 2000-08-15
HUP0002048A3 (en) 2002-09-30
EP1034001B1 (en) 2004-08-04
TR199903141T2 (xx) 2000-09-21
NO996274L (no) 2000-02-18
DE69825473D1 (de) 2004-09-09
CN1651071A (zh) 2005-08-10
EA002512B1 (ru) 2002-06-27
KR20010013964A (ko) 2001-02-26
NZ502051A (en) 2001-04-27
US20020119151A1 (en) 2002-08-29
NO996274D0 (no) 1999-12-17
SK285962B6 (sk) 2007-12-06
IS2097B (is) 2006-04-12
IL133305A0 (en) 2001-04-30
JP2002504910A (ja) 2002-02-12
HUP0002048A2 (hu) 2000-10-28
HK1031825A1 (en) 2001-06-29
CN1261285A (zh) 2000-07-26

Similar Documents

Publication Publication Date Title
IS5274A (is) Lækningameðferð, sem felst í CD 154 hindrun, við lækningaprótínstálmaheilkenni
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
EP2409985A3 (en) Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
BG102668A (en) Application of ppar-alpha and prar-gamma antagonist for the treatment of syndrome x
AU3419995A (en) Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU3664401A (en) Platelet adp receptor inhibitors
WO2002010137A3 (en) Indazole derivatives as JNK inhibitors
BR9811099A (pt) Inibidores de urocinase
MY114347A (en) Synergistic therapeutic compositions and methods.
UA72909C2 (en) Cinnamide derivatives useful in the treatment of inflammatory and immune diseases, a composition containing such derivatives and a method for the preparation of cinnamide derivatives
ES2119094T3 (es) Inhibicion de la hemorragia uterina disfuncional.
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
AU5170400A (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
DE69231384D1 (de) Zusammensetzungen zur behandlung des chronischen erschöpfungs-syndroms
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
PL327472A1 (en) Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes
IL114808A0 (en) Combination therapy for hiv
ATE369847T1 (de) Aminoguanidine zur behandlung von diabetes typ ii
MX9704579A (es) Composicion farmaceutica que comprende mirtazapina y uno o mas inhibidores selectivos de reabsorcion de serotonina.